Literature DB >> 19843950

Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses.

Caylib A Durand1, Karsten Hartvigsen, Linda Fogelstrand, Shin Kim, Sally Iritani, Bart Vanhaesebroeck, Joseph L Witztum, Kamal D Puri, Michael R Gold.   

Abstract

B-1 and marginal zone (MZ) B cells produce natural Abs, make Ab responses to microbial pathogens, and contribute to autoimmunity. Although the delta isoform of the PI3K p110 catalytic subunit is essential for development of these innate-like B cells, its role in the localization, activation, and function of normal B-1 and MZ B cells is not known. Using IC87114, a highly selective inhibitor of p110delta enzymatic activity, we show that p110delta is important for murine B-1 and MZ B cells to respond to BCR clustering, the TLR ligands LPS and CpG DNA, and the chemoattractants CXCL13 and sphingosine 1-phosphate. In these innate-like B cells, p110delta activity mediates BCR-, TLR- and chemoattractant-induced activation of the Akt prosurvival kinase, chemoattractant-induced migration, and TLR-induced proliferation. Moreover, we found that TLR-stimulated Ab responses by B-1 and MZ B cells, as well as the localization of MZ B cells in the spleen, depend on p110delta activity. Finally, we show that the in vivo production of natural Abs requires p110delta and that p110delta inhibitors can reduce in vivo autoantibody responses. Thus, targeting p110delta may be a novel approach for regulating innate-like B cells and for treating Ab-mediated autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843950     DOI: 10.4049/jimmunol.0900432

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

Review 1.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

Review 2.  The double life of a B-1 cell: self-reactivity selects for protective effector functions.

Authors:  Nicole Baumgarth
Journal:  Nat Rev Immunol       Date:  2010-12-10       Impact factor: 53.106

3.  CR2+ marginal zone B cell production of pathogenic natural antibodies is C3 independent.

Authors:  Keith M Woods; Michael R Pope; Sara M Hoffman; Sherry D Fleming
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

Review 4.  The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia.

Authors:  Kruti Sheth Nair; Bruce Cheson
Journal:  Ther Adv Hematol       Date:  2016-02-03

Review 5.  Phosphoinositide 3-kinase inhibitors in lymphoma.

Authors:  Emily Curran; Sonali M Smith
Journal:  Curr Opin Oncol       Date:  2014-09       Impact factor: 3.645

Review 6.  PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.

Authors:  Lomon So; David A Fruman
Journal:  Biochem J       Date:  2012-03-15       Impact factor: 3.857

7.  CD19 and BAFF-R can signal to promote B-cell survival in the absence of Syk.

Authors:  Elias Hobeika; Ella Levit-Zerdoun; Vasiliki Anastasopoulou; Roland Pohlmeyer; Simon Altmeier; Ameera Alsadeq; Marc-Werner Dobenecker; Roberta Pelanda; Michael Reth
Journal:  EMBO J       Date:  2015-01-28       Impact factor: 11.598

8.  Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Authors:  Sarah E M Herman; Amber L Gordon; Amy J Wagner; Nyla A Heerema; Weiqiang Zhao; Joseph M Flynn; Jeffrey Jones; Leslie Andritsos; Kamal D Puri; Brian J Lannutti; Neill A Giese; Xiaoli Zhang; Lai Wei; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-06-03       Impact factor: 22.113

9.  The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

Authors:  K Balakrishnan; M Peluso; M Fu; N Y Rosin; J A Burger; W G Wierda; M J Keating; K Faia; S O'Brien; J L Kutok; V Gandhi
Journal:  Leukemia       Date:  2015-04-28       Impact factor: 11.528

10.  Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Authors:  Matthew R Janes; Jose J Limon; Lomon So; Jing Chen; Raymond J Lim; Melissa A Chavez; Collin Vu; Michael B Lilly; Sharmila Mallya; S Tiong Ong; Marina Konopleva; Michael B Martin; Pingda Ren; Yi Liu; Christian Rommel; David A Fruman
Journal:  Nat Med       Date:  2010-01-13       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.